Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Valuation Insights | Analysts set average price target of $23.20, with estimates ranging from $18 to $29, reflecting diverse views on Kenvue's growth potential and market challenges |
Strategic Shift | Delve into Kenvue's new management initiatives, focusing on operational simplification and innovation to drive growth and address underperformance in key segments |
Financial Headwinds | Kenvue faces challenges across all segments, with revised 2025 outlook projecting low-single-digit declines in organic sales, down from previous growth estimates |
Tylenol Turmoil | Explore the impact of acetaminophen controversy on Kenvue's market position and the potential long-term implications for its flagship brand |
Metrics to compare | KVUE | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipKVUEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 22.5x | 27.6x | 11.8x | |
PEG Ratio | 0.64 | 0.09 | 0.03 | |
Price / Book | 3.0x | 2.5x | 1.5x | |
Price / LTM Sales | 2.1x | 1.8x | 0.9x | |
Upside (Analyst Target) | 9.3% | 42.8% | 21.4% | |
Fair Value Upside | Unlock | 17.9% | 12.0% | Unlock |